Education
About Us
Working with TipRanks
Follow Us
Fluicell AB (SE:FLUI)
:FLUI
Top Page
Fluicell AB
(FLUI)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr10.00
▲(0.00% Upside)
The score is mainly constrained by weak financial sustainability (ongoing losses and negative operating/free cash flow) and a bearish technical backdrop (price below key moving averages with negative MACD). Improvements in TTM revenue/losses and a zero-debt balance sheet help, but do not fully offset cash burn and trend weakness.
Fluicell AB (FLUI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr13.87M
Dividend YieldN/A
Average Volume (3M)16.23K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.09
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.88
Price to Sales (P/S)9.14
P/FCF Ratio-1.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fluicell AB Business Overview & Revenue Model
Company DescriptionFluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.
How the Company Makes Money
Fluicell AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.68M | 1.86M | 3.34M | 3.25M | 2.60M | 4.63M |
| Gross Profit | 5.25M | 3.76M | 1.74M | 2.59M | 1.89M | 3.65M |
| EBITDA | -9.32M | -14.99M | -25.91M | -20.89M | -21.08M | -16.42M |
| Net Income | -9.86M | -15.51M | -26.55M | -21.49M | -21.72M | -18.15M |
Balance Sheet | ||||||
| Total Assets | 16.38M | 25.51M | 9.34M | 31.77M | 26.98M | 24.83M |
| Cash, Cash Equivalents and Short-Term Investments | 990.00K | 15.92M | 2.76M | 24.46M | 20.69M | 18.80M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.58M | 6.27M | 8.91M | 8.32M | 7.87M | 5.33M |
| Stockholders Equity | 10.80M | 19.23M | 425.00K | 23.45M | 19.11M | 19.50M |
Cash Flow | ||||||
| Free Cash Flow | -13.24M | -15.67M | -27.23M | -22.18M | -19.41M | -17.90M |
| Operating Cash Flow | -6.21M | -15.67M | -27.23M | -21.04M | -18.64M | -17.57M |
| Investing Cash Flow | -10.52M | -3.49M | 0.00 | -1.14M | -772.00K | -331.00K |
| Financing Cash Flow | 150.00K | 32.32M | 5.53M | 25.94M | 21.31M | 28.26M |
Fluicell AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:FLUI
Fluicell AB
10.40
-8.22
-44.14%
DE:9F1
Diagonal Bio AB
0.10
0.00
0.00%
DE:5LD
LIDDS AB
0.01
0.00
0.00%
DE:65G
NextCell Pharma AB
0.05
-0.16
-76.81%
DE:COJ0
CombiGene AB
0.16
<0.01
1.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.